Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quetiapine
Drug ID BADD_D01888
Description Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [Clozapine] and [Olanzapine].[A2189]
Indications and Usage Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546] Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]
Marketing Status approved
ATC Code N05AH04
DrugBank ID DB01224
KEGG ID D08456
MeSH ID D000069348
PubChem ID 5002
TTD Drug ID D0H7KF
NDC Product Code 0310-0530; 16729-145; 16729-149; 16714-453; 16714-454; 0093-8163; 50228-380; 0310-0280; 0310-0283; 60687-327; 65862-877; 68001-182; 68001-183; 68001-185; 80425-0107; 16729-146; 16729-150; 0310-0282; 60687-338; 63629-2479; 63629-2481; 65862-875; 70518-0752; 71093-136; 71205-402; 16729-147; 16714-455; 16714-457; 0093-8162; 42291-695; 42291-698; 42291-700; 43547-020; 0310-0272; 0310-0274; 0310-0278; 0310-0284; 68001-181; 70518-0239; 0310-0279; 60687-382; 65862-874; 71093-137; 0615-7987; 0310-0505; 43547-019; 50090-2830; 60687-349; 60687-371; 63629-2478; 63629-2480; 63629-2482; 63629-7116; 71093-138; 0615-7986; 0615-8119; 16714-452; 16714-456; 0093-8166; 33342-135; 43547-519; 71093-135; 72789-255; 80425-0143; 0093-2063; 0093-8164; 42291-699; 43547-520; 43547-522; 43547-523; 50090-2338; 50228-382; 50228-383; 0310-0271; 68001-184; 70518-0289; 71093-139; 16729-148; 29300-309; 50090-4788; 53002-1516; 0310-0275; 0310-0281; 60687-360; 65862-876; 70518-0570; 71205-026; 71610-702; 0310-0515; 0093-8165; 29300-308; 29300-310; 29300-311; 29300-312; 33342-136; 42291-696; 43547-021; 68001-180; 68788-7186; 70518-2828; 0615-7988; 0310-0520; 0310-0540; 33342-137; 42291-697; 43547-518; 43547-521; 50228-384; 65862-873; 71205-401; 0615-8118; 33342-134; 43547-022; 50228-381; 53002-1529
UNII BGL0JSY5SI
Synonyms Quetiapine Fumarate | Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt) | Seroquel | ICI 204,636 | ICI-204636 | ICI204636 | ICI 204636 | Quetiapine | 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
Chemical Information
Molecular Formula C21H25N3O2S
CAS Registry Number 111974-69-7
SMILES C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metabolic syndrome14.06.02.007; 05.06.02.007; 24.08.02.0140.000109%Not Available
Haemodynamic instability24.03.02.0060.000082%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.0270.000561%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Delusional disorder, persecutory type19.03.03.0010.000055%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000082%Not Available
Depressive symptom19.15.02.0030.000082%Not Available
Nodule08.03.05.0020.000120%Not Available
Affect lability19.04.01.001--Not Available
Cerebral disorder17.02.10.0170.000055%Not Available
Dysphemia19.19.03.005; 17.02.08.010--Not Available
Foetal death18.01.02.003; 08.04.01.0110.000082%
Haemorrhage24.07.01.002--Not Available
Parkinsonian gait17.01.05.005; 08.01.02.005--Not Available
Faecaloma07.01.03.0040.000191%Not Available
Food craving19.09.01.010; 14.03.01.0090.000082%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000055%Not Available
Bipolar disorder19.16.01.0030.000976%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000714%
Metabolic disorder14.11.01.0010.000213%Not Available
Dyslipidaemia14.08.04.0150.000082%Not Available
Pulseless electrical activity02.03.04.0200.000055%Not Available
Orchitis noninfective21.09.02.003--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.001292%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Bicytopenia01.03.03.0100.000055%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 26 Pages